ABBV - Alpine Immune Sciences inks deal with AbbVie for lead drug June, 18 2020 08:25 AM AbbVie Inc. Alpine Immune Sciences (NASDAQ:ALPN) enters into an exclusive global option and license agreement with AbbVie (NYSE:ABBV) for lead candidate ALPN-101.More news on: Alpine Immune Sciences, Inc., AbbVie Inc., Healthcare stocks news, Read more ...